The $14.5m second tranche followed milestones towards clinical trials and came from MedImmune Ventures, a US-based corporate venturing unit of drugs company AstraZeneca, and venture capital firms SV Life Sciences, Advanced Technology Ventures and Clarus Ventures.
Catabasis Pharmaceuticals, a US-based biopharmaceutical company for diabetes, has drawn down the second tranche of its $39.6m series A round raised in April.
The $14.5m second tranche followed milestones towards clinical trials and came from MedImmune Ventures, a US-based corporate venturing unit of drugs company AstraZeneca, and venture capital firms SV Life Sciences, Advanced Technology Ventures and Clarus Ventures.
In April, Maggie Flanagan LeFlore, managing director at MedImmune Ventures, said: "Type 2 diabetes is an area of high unmet need…
